BioSpace News Archive

Colorcon, a world leader in the development and supply of film coating systems and excipients, announces SoteriaRx™.

INOVIO (NASDAQ: INO) today announced that 85 percent (44 out of 52) of patients newly diagnosed with the deadly brain cancer glioblastoma multiforme (GBM) who received the company’s DNA medicine INO-5401, in combination with INO-9012 and PD-1 inhibitor Libtayo® (cemiplimab), were alive for at least 12 months or more (overall survival at 12 months: OS12) following treatment

C-Level Speakers from The Centers for Disease Control, Cleveland Clinic, U.S. Army, Accenture, Biogen, The NBA’s Boston Celtics, State of Florida, BMO and other Top Organizations to Discuss How to Return to Work, Utilize Contact Tracing and Manage Operations to Best Mitigate the Risk of COVID-19.

Foundation Medicine, Inc. today announced that new data supporting the clinical use of its portfolio of tissue and liquid comprehensive genomic profiling (CGP) tests will be presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, which will be held from May 29 to May 31.

Frequency Therapeutics, Inc. (Nasdaq: FREQ), today announced top-line data from an exploratory clinical study designed to show whether drug levels of FX-322 in the cochlea can be directly measured. In addition to confirming the viability of the approach, study results showed measurable concentrations of FX-322 in every patient and that anatomical factors

Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter 2020 on Wednesday, May 27, 2020. The Company has scheduled a conference call for that same day, Wednesday, May 27, 2020 at 11:00am ET (4:00pm BST) to discuss the results of the quarter. Interested parties can access the call by dialing:

Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that topline data of the recently completed L-DOS47 dose escalation study in combination with pemetrexed and carboplatin in recurrent or metastatic non-squamous non-small cell lung cancer (“LDOS001”) will be published at the ASCO 2020 Annual Conference. The A

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2020 and provided a clinical and corporate update. “While the NODE-301 trial of et

- Upfront payment of $50m received from Astellas and approximately $90m offering completed - - Financial guidance confirmed: funded into 2H 2021 - - Orphan Drug Designation positive opinion for ADP-A2M4 in the EU adds to US FDA ODD and RMAT designations - - Upcoming presentations at major scientific meetings with data from ADP-A2M4, ADP-A2AFP, and allogeneic programs - - Conference call to be held today at 8:00 a.m. EDT (1:00 p.m. BST) - PHILADELPHIA and OXFORDSHIRE, United Kin

Soliton, Inc., a medical device company with a novel and proprietary platform technology, reported financial results for the first quarter ended March 31, 2020.